{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:26:33Z","timestamp":1790889993526,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,24]]},"DOI":"10.1097\/qad.0b013e328351a521","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T04:28:29Z","timestamp":1329193709000},"page":"833-841","source":"Crossref","is-referenced-by-count":32,"title":["Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women"],"prefix":"10.1097","volume":"26","author":[{"given":"Betty J.","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Frymoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Verotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lizak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Sawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S.","family":"Currier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Lockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca T.","family":"Aweeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1545109707299356","article-title":"Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda.","volume":"6","author":"Hahn","year":"2007","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.","volume":"15","author":"Martinez","year":"2001","journal-title":"AIDS"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1468-1293.2010.00873.x","article-title":"Nevirapine-associated hepatotoxicity was not predicted by CD4 count 250cellsmuL among women in Zambia, Thailand and Kenya.","volume":"11","author":"Peters","year":"2010","journal-title":"HIV Med"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"e12617","DOI":"10.1371\/journal.pone.0012617","article-title":"Adverse events in a cohort of HIV infected pregnant and nonpregnant women treated with nevirapine versus nonnevirapine antiretroviral medication.","volume":"5","author":"Aaron","year":"2010","journal-title":"PLoS One"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1086\/317536","article-title":"Sex differences in nevirapine rash.","volume":"32","author":"Bersoff-Matcha","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/aid.2005.21.555","article-title":"Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.","volume":"21","author":"De Requena","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/0889222041524670","article-title":"The relationship between nevirapine plasma concentrations and abnormal liver function tests.","volume":"20","author":"Almond","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1310\/hct0806-391","article-title":"Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites.","volume":"8","author":"Hall","year":"2007","journal-title":"HIV Clin Trials"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00228-003-0613-3","article-title":"Incidence and risk factors for nevirapine-associated rash.","volume":"59","author":"de Maat","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1097\/00002030-200009290-00012","article-title":"Prevention of nevirapine-associated exanthema using slow dose escalation andor corticosteroids.","volume":"14","author":"Barreiro","year":"2000","journal-title":"AIDS"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations.","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jac\/dkr087","article-title":"Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.","volume":"66","author":"Schipani","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/00002030-200311070-00018","article-title":"Sex differences in nevirapine disposition in HIV-infected patients.","volume":"17","author":"Regazzi","year":"2003","journal-title":"AIDS"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/QAI.0b013e31819c3376","article-title":"Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.","volume":"50","author":"Gandhi","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1046\/j.1365-2125.2002.01657.x","article-title":"Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.","volume":"54","author":"de Maat","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2125.2006.02664.x","article-title":"A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.","volume":"62","author":"von Hentig","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa0906626","article-title":"Antiretroviral therapies in women after single-dose nevirapine exposure.","volume":"363","author":"Lockman","year":"2010","journal-title":"N Engl J Med"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/AAC.43.1.121","article-title":"Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.","volume":"43","author":"Zhou","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1258\/095646206777323346","article-title":"Nevirapine toxicity.","volume":"17","author":"Taiwo","year":"2006","journal-title":"Int J STD AIDS"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1086\/324088","article-title":"Sex differences in nevirapine rash.","volume":"33","author":"Wong","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00007691-200408000-00018","article-title":"Race is not associated with nevirapine pharmacokinetics.","volume":"26","author":"de Maat","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1310\/B5VU-FU5F-QNWC-UDCK","article-title":"Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.","volume":"6","author":"Kappelhoff","year":"2005","journal-title":"HIV Clin Trials"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/135965350501000114","article-title":"Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jac\/dkn268","article-title":"Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.","volume":"62","author":"Molto","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/ps020101","article-title":"Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.","volume":"2","author":"Sabo","year":"2000","journal-title":"AAPS Pharm Sci"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1097\/00002030-200005260-00001","article-title":"The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.","volume":"14","author":"van Heeswijk","year":"2000","journal-title":"AIDS"},{"key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1468-1293.2009.00721.x","article-title":"Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.","volume":"10","author":"Dailly","year":"2009","journal-title":"HIV Med"},{"key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00228-004-0769-5","article-title":"No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.","volume":"60","author":"Dailly","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"R31-8-20210130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.","volume":"13","author":"Stohr","year":"2008","journal-title":"Antivir Ther"},{"key":"R32-8-20210130","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/382754","article-title":"Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.","volume":"189","author":"Fletcher","year":"2004","journal-title":"J Infect Dis"},{"key":"R33-8-20210130","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1177\/0091270010388650","article-title":"Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.","volume":"51","author":"Umeh","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R34-8-20210130","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00002030-200201250-00020","article-title":"Liver toxicity caused by nevirapine.","volume":"16","author":"Gonzalez de Requena","year":"2002","journal-title":"AIDS"},{"key":"R35-8-20210130","first-page":"249","article-title":"Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.","volume":"39","author":"Crommentuyn","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R36-8-20210130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.","volume":"363","author":"van Leth","year":"2004","journal-title":"The Lancet"},{"key":"R37-8-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R38-8-20210130","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0b013e3282ef9695","article-title":"CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.","volume":"21","author":"Saitoh","year":"2007","journal-title":"AIDS"},{"key":"R39-8-20210130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/597125","article-title":"Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.","volume":"199","author":"Haas","year":"2009","journal-title":"J Infect Dis"},{"key":"R40-8-20210130","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"R41-8-20210130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/pgs.09.142","article-title":"Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.","volume":"11","author":"Ciccacci","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R42-8-20210130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/507097","article-title":"Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.","volume":"43","author":"Haas","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R43-8-20210130","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00126334-200404150-00014","article-title":"Hepatotoxicity associated with nevirapine use.","volume":"35","author":"Baylor","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R45-8-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-10-188","article-title":"Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote dIvoire.","volume":"10","author":"Coffie","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R46-8-20210130","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.","volume":"44","author":"Nunez","year":"2006","journal-title":"J Hepatol"},{"key":"R47-8-20210130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QAD.0b013e3283323941","article-title":"Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.","volume":"24","author":"Ouyang","year":"2010","journal-title":"AIDS"},{"key":"R48-8-20210130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1310\/hct1101-11","article-title":"Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study.","volume":"11","author":"Antela","year":"2010","journal-title":"HIV Clin Trials"},{"key":"R49-8-20210130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-1293.2008.00513.x","article-title":"Risk of side effects associated with the use of nevirapine in treatment-naive patients, with respect to gender and CD4 cell count.","volume":"9","author":"Knobel","year":"2008","journal-title":"HIV Med"},{"key":"R50-8-20210130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/infdis\/169.1.28","article-title":"Within-Subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring.","volume":"169","author":"Hughes","year":"1994","journal-title":"J Infect Dis"},{"key":"R51-8-20210130","first-page":"144","article-title":"Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important.","volume":"3","author":"Malone","year":"1990","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R53-8-20210130","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1086\/508206","article-title":"HIV infection, antiretroviral therapy, and CD4 cell count distributions in African populations.","volume":"194","author":"Williams","year":"2006","journal-title":"J Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-201204240-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:38:41Z","timestamp":1786048721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201204240-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,24]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328351a521","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4,24]]}}}